And finally, tau aggregation inhibitors have been one of the most anticipated disease-modifying therapies for Alzheimer’s disease, but have unfortunately failed to deliver its promises with its most recent example, TRx0237, that entered three phase III trials and failed to slow cognitive or functional decline in people with mild to moderate Alzheimer’s disease compared to the placebo groups [45]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.